Hossein Hosseinkhani

Publications (83) View all

• Source

  Available from: Hossein Hosseinkhani

  Article: Self-Assembled Proteins and Peptides for Regenerative Medicine.

  Hossein Hosseinkhani, Po-Da Hong, Dah-Shyong Yu
  Chemical Reviews 04/2013; · 40.20 Impact Factor
• Source

  Available from: Hossein Hosseinkhani

  Article: Engineering of magnetic DNA nanoparticles for tumor-targeted therapy

  Hossein Hosseinkhani, Yi-Ru Chen, Wenjie He, Po-Da Hong, Dah-Shyong Yu, Abraham J. Domb
  [show abstract] [hide abstract]
  ABSTRACT: This study aims to engineer novel targeted delivery system composed of magnetic DNA nanoparticles to be effective as an efficient targeted gene therapy vehicle for tumor therapy. A polysaccharide, dextran, was chosen as the vector of plasmid DNAencoded NK4 that acts as an HGF-antagonist and antiangiogenic regulator for inhibitions of tumor growth, invasion, and metastasis. Spermine (Sm) was chemically introduced to the hydroxyl groups of dextran to obtain dextran-Sm. When Fe2? solution was added to the mixture of dextran-Sm and a plasmid DNA, homogenous DNA nanoparticles were formed via chemical metal coordination bonding with average size of 230 nm. Characterization ofDNAnanoparticles was performed via dynamic light scattering measurement, electrophoretic light scattering measurement, as well as transmission electron microscope. DNA nanoparticles effectively condensed plasmid DNA into nanoparticles and enhanced the stability of DNA, while significantly improved transfection efficiency in vitro and tumor accumulation in vivo. In addition, magnetic DNA nanoparticles exhibited high efficiency in antitumor therapy with regards to tumor growth as well as survival of animals evaluated in the presence of external magnetic field. We conclude that the magnetic properties of these DNA nanoparticles would enhance the tracking of non-viral gene delivery systems when administrated in vivo in a test model. These findings suggest that DNA nanoparticles effectively deliver DNA to tumor and thereby inhibiting tumor growth.
  Journal of Nanoparticle Research 01/2013; 15(1):1-10. · 3.29 Impact Factor
• Source

  Available from: Hossein Hosseinkhani

  Chapter: Controlled Release Systems for Bone Regeneration

  Hossein Hosseinkhani, Mohsen Hosseinkhani
  [show abstract] [hide abstract]
  ABSTRACT: 24.1  Overview Bone defects and fracture nonunion are common problems, affecting as many as 1000 patients in the world every year, and are difficult to heal using current therapies. Previously, these cases have been treated by surgery, using techniques such as autologous bone grafting or artificial bone graft-ing. However, autologous bone grafts have a number of problems including donor-site problems, the limitations of harvested bone, or the weak strength of graft-bone, while artificial bone grafts also have associated problems caused by the use of biomaterials, including immunogenicity, biodegrada-tion, or strength limitations. Bone regeneration is an attractive research field of tissue engineering because of its high clinical requirement. It is widely recognized that various osteogenic growth factors regulate the proliferation and differentiation of osteogenic cells and enhance bone forma-tion. However, the use of osteogenic growth factor alone requires large amounts of protein because of its short half-life. Furthermore, the response to osteogenic growth factor varies between human species and primates need larger amounts of osteogenic growth factor than rodents. Aging has also been reported to lead to a reduction in response. To overcome these problems and to reduce the amounts of osteogenic growth factor required, developments in new types of materials by use of drug delivery systems (DDS) and combined treatments with other reagents that can enhance bone regeneration are challenging. Thus, if one can accelerate bone regeneration using osteogenic growth factors in a suitable manner, this regeneration technology will provide a new clinical procedure bone repair and be substituted for autogenous and allogenous bone grafts or biomaterial implants. This chapter reviews the basic principle of controlled release systems and the recent developments of new materials for their potential applications in regenerative medicine therapy for bone regen-eration. This chapter emphasizes that controlled release technology in combination with principle of tissue engineering represents a viable strategy for the development of certain engineered tissue replacements and tissue regeneration systems to enhance bone regeneration.
  01/2013: pages 643-654;
• Conference Proceeding: 3D In Vitro Living Systems for Biological Application

  Hossein Hosseinkhani
  Proceedings of Animal Alternatives in Teaching, Toxicity Testing and Medicine, India; 01/2013
• Source

  Available from: Hossein Hosseinkhani

  Article: Polysaccharide gene transfection agents.

  Wahid Khan, Hossein Hosseinkhani, Diana Ickowicz, Po-Da Hong, Da-Shyong Yu, Abraham J Domb
  [show abstract] [hide abstract]
  ABSTRACT: Gene delivery is a promising technique that involves in vitro or in vivo introduction of exogenous genes into cells for experimental and therapeutic purposes. Successful gene delivery depends on the development of effective and safe delivery vectors. Two main delivery systems, viral and non-viral gene carriers, are currently deployed for gene therapy. While most current gene therapy clinical trials are based on viral approaches, non-viral gene medicines have also emerged as potentially safe and effective for the treatment of a wide variety of genetic and acquired diseases. Non-viral technologies consist of plasmid-based expression systems containing a gene associated with the synthetic gene delivery vector. Polysaccharides compile a large family of heterogenic sequences of monomers with various applications and several advantages as gene delivery agents. This chapter, compiles the recent progress in polysaccharide based gene delivery, it also provides an overview and recent developments of polysaccharide employed for in vitro and in vivo delivery of therapeutically important nucleotides, e.g. plasmid DNA and small interfering RNA.
  Acta biomaterialia 09/2012; · 3.98 Impact Factor